Clinical Trial: IMM60 and Pembrolizumab in Melanoma and NSCLC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non-small Cell Lung Cancer
Study Type: INTERVENTIONAL
Official Title: IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC
Brief Summary:
The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in participants with advanced melanoma or non-small cell lung cancer.There are two phases:Phase 1: This phase is designed to learn about the safety of IMM60 with or without pembrolizumab and to find a safe dose to test in Phase 2.Phase 2: This phase is designed to learn whether IMM60 + pembrolizumab improves progression-free survival at 12 months compared to pembrolizumab alone in participants with non-small cell lung cancer.
Read more